Research Analysts Set Expectations for RCUS FY2025 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS) – HC Wainwright dropped their FY2025 EPS estimates for shares of Arcus Biosciences in a report released on Tuesday, February 18th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($4.69) per share for the year, down from their previous forecast of ($3.54). HC Wainwright currently has a “Neutral” rating and a $18.00 price objective on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.20) per share. HC Wainwright also issued estimates for Arcus Biosciences’ FY2026 earnings at ($5.44) EPS, FY2027 earnings at ($5.62) EPS and FY2028 earnings at ($2.81) EPS.

A number of other brokerages also recently commented on RCUS. Barclays increased their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Morgan Stanley lowered their price target on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a report on Tuesday. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. Finally, Bank of America lowered their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.50.

Arcus Biosciences Stock Up 3.0 %

RCUS opened at $11.06 on Friday. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. Arcus Biosciences has a 52 week low of $10.63 and a 52 week high of $20.31. The firm has a 50-day simple moving average of $13.92 and a two-hundred day simple moving average of $15.55. The company has a market capitalization of $1.01 billion, a PE ratio of -3.51 and a beta of 0.84.

Hedge Funds Weigh In On Arcus Biosciences

A number of institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Arcus Biosciences by 2.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company’s stock worth $506,000 after acquiring an additional 833 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Arcus Biosciences by 2.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,781 shares of the company’s stock worth $471,000 after acquiring an additional 843 shares during the period. JPMorgan Chase & Co. increased its position in shares of Arcus Biosciences by 2.6% during the third quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company’s stock worth $668,000 after acquiring an additional 1,117 shares during the period. R Squared Ltd purchased a new position in shares of Arcus Biosciences during the fourth quarter worth approximately $26,000. Finally, Teacher Retirement System of Texas increased its position in shares of Arcus Biosciences by 19.2% during the fourth quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company’s stock worth $223,000 after acquiring an additional 2,410 shares during the period. 92.89% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the sale, the chief financial officer now owns 60,138 shares of the company’s stock, valued at $902,070. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 12.30% of the stock is owned by insiders.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.